John Violet
YOU?
Author Swipe
Acute exercise induces distinct quantitative and phenotypical T cell profiles in men with prostate cancer Open
Background Reduced testosterone levels can influence immune system function, particularly T cells. Exercise during cancer reduces treatment-related side effects and provide a stimulus to mobilize and redistribute immune cells. However, it …
Natural killer cell mobilization and egress following acute exercise in men with prostate cancer Open
New Findings What is the central question of this study? What are the characteristics of the NK cell response following acute moderate‐intensity aerobic exercise in prostate cancer survivors and is there a relationship between stress hormo…
Attenuation of Resting but Not Load-Mediated Protein Synthesis in Prostate Cancer Patients on Androgen Deprivation Open
Context: Androgen deprivation therapy (ADT) is a common prostate cancer (PCa) treatment but results in muscular atrophy. Periodic increases in muscle protein synthesis (MPS) that occur after resistance exercise or protein intake may amelio…
Radiation Dosimetry in <sup>177</sup>Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors Open
Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative approach is to take advantage of existing pharmacokinetic data…
View article: Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer Open
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase I…
TheraP: a randomized phase 2 trial of <sup>177</sup> Lu‐ <span>PSMA</span> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <span>ANZUP</span> 1603) Open
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu‐ PSMA ‐617, a novel radiolabelled small molecule that binds with high affinity to prostate‐specific membrane antigen ( PSMA ), in men …
View article: Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes Open
177Lu-prostate-specific membrane antigen (PSMA)-617 enables targeted delivery of β-particle radiation to prostate cancer. We determined its radiation dosimetry and relationships to pretherapeutic imaging and outcomes. Methods: Thirty patie…
Altered stress hormone response following acute exercise during prostate cancer treatment Open
Exercise training reduces the side effects of cancer treatments; however, the stress hormone response to acute exercise during prostate cancer ( PC a) treatment is unclear. The study purpose was to examine the effects of acute exercise on …
Prostate‐specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer Open
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Lutetium <sup>177</sup> PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy Open
Prostate‐specific membrane antigen ( PSMA ) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the P…
Attenuation of Resting but Not Load-Mediated Protein Synthesis in Prostate Cancer Patients on Androgen Deprivation Open
ADT reduces basal and protein feeding-induced rises in MPS; however, combined protein ingestion with resistance exercise stimulated MPS to a similar degree as CON. Testosterone appears to play a role in maintaining muscle mass but is not n…